Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 125 of 127 entries
View as:

To Evaluate the Efficacy and Safety of AK111 Injection in the Treatment of Moderate to Severe Plaque Psoriasis

Phase: N/A Priority: Normal
NCT ID: NCT06061471 Org: User:
Start: 09/22/23 End: 12/11/24 Due: 12/11/25

A Phase I Study of AK138D1 in the Treatment of Advanced Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT06730386 Org: User:
Start: 02/24/25 End: 08/30/28 Due: 08/30/29

A Study of AK104 in Subjects With Unresectable Locally Advanced NSCLC

Phase: N/A Priority: Normal
NCT ID: NCT06617416 Org: User:
Start: 11/12/24 End: 12/30/28 Due: 12/30/29

Study of AK119 and AK112 With or Without Chemotherapy for NSCLC Patients

Phase: N/A Priority: Normal
NCT ID: NCT05636267 Org: User:
Start: 02/10/23 End: 03/31/25 Due: 03/31/26

A Trial of AK104 Plus Anlotinib in NSCLC

Phase: N/A Priority: Normal
NCT ID: NCT04646330 Org: User:
Start: 11/18/20 End: 07/31/25 Due: 07/31/26

A Study of AK117/AK112 in Metastatic Triple-Negative Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT05227664 Org: User:
Start: 03/23/22 End: 12/30/26 Due: 12/30/27

A Phase Ib/II Clinical Study on AK112 Combined or Not Combined With AK119 in pMMR/MSS Colorectal Cancer

Phase: N/A Priority: Normal
NCT ID: NCT05846867 Org: User:
Start: 05/08/23 End: 08/11/26 Due: 08/11/27

A Phase 1 Dose Escalation and Expansion Study of AK117

Phase: N/A Priority: Normal
NCT ID: NCT04728334 Org: User:
Start: 03/23/21 End: 05/12/23 Due: 05/12/24

A Study of AK104, a PD-1/CTLA-4 Bispecific Antibody in Subjects With Recurrent/Metastatic Cervical Cancer

Phase: N/A Priority: Normal
NCT ID: NCT04380805 Org: User:
Start: 07/15/20 End: 01/31/23 Due: 01/31/24

A Phase III Study of AK104 as Adjuvant Therapy in HCC With High Risk of Recurrence After Curative Resection

Phase: N/A Priority: Normal
NCT ID: NCT05489289 Org: User:
Start: 01/05/23 End: 01/01/27 Due: 01/01/28

A Study of AK104, a PD-1/CTLA-4 Bispecific Antibody, for Advanced Solid Tumors or With mXELOX/XELOX as First-line Therapy for Advanced Gastric or GEJ Adenocarcinoma

Phase: N/A Priority: Normal
NCT ID: NCT03852251 Org: User:
Start: 01/18/19 End: 03/25/24 Due: 03/25/25

A Study to Evaluate the Safety, Pharmacokinetics, and Antitumor Activity of AK114

Phase: N/A Priority: Normal
NCT ID: NCT05200273 Org: User:
Start: 03/15/22 End: 12/30/23 Due: 12/30/24

A Clinical Study of AK120 in Adolescents With Moderate-to-severe Atopic Dermatitis

Phase: N/A Priority: Normal
NCT ID: NCT06767540 Org: User:
Start: 01/23/25 End: 07/10/27 Due: 07/10/28

A Phase Ib/II Study of AK104 and AK117 in Combination With or Without Chemotherapy in Advanced Malignant Tumors

Phase: N/A Priority: Normal
NCT ID: NCT05235542 Org: User:
Start: 07/12/22 End: 03/31/24 Due: 03/31/25

A Clinical Study of AK115 in Healthy Subjects

Phase: N/A Priority: Normal
NCT ID: NCT05286970 Org: User:
Start: 03/18/22 End: 09/28/22 Due: 09/28/23

A Study of PD-1/CTLA-4 Bispecific AK104 in Relapsed or Refractory Peripheral T-cell Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT04444141 Org: User:
Start: 05/15/20 End: 09/30/22 Due: 09/30/23

A Clinical Study of AK101 in Subjects With Moderate to Severe Plaque Psoriasis

Phase: N/A Priority: Normal
NCT ID: NCT04172233 Org: User:
Start: 01/09/18 End: 10/31/19 Due: 10/31/20

A Study of Penpulimab Combination Therapy in Patients With Advanced Nasopharyngeal Carcinoma

Phase: N/A Priority: Normal
NCT ID: NCT04736810 Org: User:
Start: 02/25/21 End: 12/18/23 Due: 12/18/24

AK137 (Bispecific Antibody Targeting CD73 and LAG-3) in Patients With Advanced Malignant Tumors

Phase: N/A Priority: Normal
NCT ID: NCT06691360 Org: User:
Start: 12/31/24 End: 08/31/27 Due: 08/31/28

A Study of AK104 in Subjects With Locally Advanced Unresectable or Metastatic MSI-H/dMMR Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT04547101 Org: User:
Start: 04/24/20 End: 09/30/22 Due: 09/30/23

A Study of AK104/Placebo Plus AK109/Placebo And Paclitaxel in Gastric or Gastroesophageal Junction Adenocarcinoma

Phase: N/A Priority: Normal
NCT ID: NCT06341335 Org: User:
Start: 06/19/24 End: 07/31/27 Due: 07/31/28

A Study of AK104 Monotherapy or AK104 Plus Axitinib in Advanced/Metastatic Renal Cell Carcinoma

Phase: N/A Priority: Normal
NCT ID: NCT05256472 Org: User:
Start: 07/06/23 End: 06/22/26 Due: 06/22/27

A Study of AK112 in Patients With Unresectable Hepatocellular Carcinoma (HCC)

Phase: N/A Priority: Normal
NCT ID: NCT05432492 Org: User:
Start: 08/31/22 End: 08/31/24 Due: 08/31/25

A Study of PCSK9 Inhibitor AK102 in Healthy Subjects

Phase: N/A Priority: Normal
NCT ID: NCT04169386 Org: User:
Start: 05/23/18 End: 11/22/18 Due: 11/22/19

A Study Evaluating the Single Subcutaneous Injection of Ebronucimab in Chinese Healthy Male Subjects

Phase: N/A Priority: Normal
NCT ID: NCT06641388 Org: User:
Start: 11/04/24 End: 06/17/25 Due: 06/17/26